SCHEMBL26676598

SCHEMBL26676598

Cc1oc2ccc(OCC(F)F)cc2c1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
HTT P42858 1/20 0.65
SLC26A4 O43511 7/20 0.63
KMT2A Q03164 6/20 0.62
MEN1 O00255 5/20 0.62
BLM P54132 1/20 0.62
ATM Q13315 1/20 0.62
POLB P06746 3/20 0.58
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
MAPK1 P28482 3/20 0.52
MAPK10 P53779 1/20 0.52
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 2/20 0.50
GAA P10253 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HPGD P15428 1/20 0.50
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26676637 0.88 SLC26A4 (0.65) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL30664734 0.86 ALDH1A1 (0.69) LMNAHTTKMT2AMEN1POLB
SCHEMBL26676560 0.86 ALDH1A1 (0.69) LMNAHTTKMT2AMEN1POLB
SCHEMBL3976556 0.84 SLC26A4 (0.69) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL26676529 0.82 LMNA (0.65) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL26676533 0.81 LMNA (0.58) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL26676568 0.81 SLC26A4 (0.65) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL30664708 0.81 SLC26A4 (0.65) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL24470655 0.80 CASP3 (0.84) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL29713158 0.80 CASP3 (0.84) LMNAHTTSLC26A4KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320189-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-10-16 US disclosed
EP-4532479-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
CN-119403794-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-07 CN disclosed
WO-2023227695-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320189-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 LMNA 3246/4885HTT 2973/4885SLC26A4 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.